Maternal serum perlecan levels in women with preeclampsia
Objective: Perlecan is an extracellular matrix proteoglycan suggested to maintain endothelial functions. We aimed to measure maternal serum perlecan levels in different preeclampsia phenotypes. Methods: This study included 50 women with preeclampsia and 30 healthy pregnant women. Results: Serum perl...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Hypertension in Pregnancy |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10641955.2019.1711390 |
Summary: | Objective: Perlecan is an extracellular matrix proteoglycan suggested to maintain endothelial functions. We aimed to measure maternal serum perlecan levels in different preeclampsia phenotypes. Methods: This study included 50 women with preeclampsia and 30 healthy pregnant women. Results: Serum perlecan levels were significantly higher (p = 0.016) in preeclamptic women with severe features(n = 23) than preeclampsia patients(n = 27). There were no statistically significant differences in serum perlecan levels between the early-onset preeclampsia(n = 25), late-onset preeclampsia(n = 25), and healthy pregnancies. Conclusion: Our findings suggest that preeclamptic women with severe features have higher serum perlecan levels than women with preeclampsia. |
---|---|
ISSN: | 1064-1955 1525-6065 |